MESSORI, LUIGI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 25.086
EU - Europa 14.880
AS - Asia 8.510
SA - Sud America 1.198
AF - Africa 202
OC - Oceania 184
Continente sconosciuto - Info sul continente non disponibili 13
Totale 50.073
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 24.902
RU - Federazione Russa 5.318
PL - Polonia 3.124
SG - Singapore 2.604
CN - Cina 2.075
HK - Hong Kong 1.555
IT - Italia 1.425
IE - Irlanda 1.267
SE - Svezia 1.240
BR - Brasile 993
KR - Corea 915
DE - Germania 617
UA - Ucraina 523
FI - Finlandia 486
VN - Vietnam 388
GB - Regno Unito 364
IN - India 295
AU - Australia 176
JO - Giordania 148
FR - Francia 123
TR - Turchia 102
CA - Canada 100
ES - Italia 89
ID - Indonesia 88
AR - Argentina 81
NL - Olanda 72
BE - Belgio 61
CH - Svizzera 59
BD - Bangladesh 53
JP - Giappone 47
CI - Costa d'Avorio 46
MX - Messico 46
ZA - Sudafrica 46
IQ - Iraq 44
EC - Ecuador 33
AT - Austria 27
VE - Venezuela 27
MA - Marocco 25
EG - Egitto 23
PK - Pakistan 23
IL - Israele 21
UZ - Uzbekistan 20
BG - Bulgaria 19
CL - Cile 19
PH - Filippine 14
CO - Colombia 13
CZ - Repubblica Ceca 13
PY - Paraguay 13
SA - Arabia Saudita 13
IR - Iran 12
KE - Kenya 11
AE - Emirati Arabi Uniti 10
AZ - Azerbaigian 10
SC - Seychelles 10
TW - Taiwan 10
LT - Lituania 8
NZ - Nuova Zelanda 8
UY - Uruguay 8
BJ - Benin 7
KG - Kirghizistan 7
KZ - Kazakistan 7
PE - Perù 7
XK - ???statistics.table.value.countryCode.XK??? 7
AL - Albania 6
DO - Repubblica Dominicana 6
DZ - Algeria 6
EU - Europa 6
HN - Honduras 6
OM - Oman 6
RO - Romania 6
TN - Tunisia 6
ET - Etiopia 5
JM - Giamaica 5
LB - Libano 5
NI - Nicaragua 5
PA - Panama 5
DK - Danimarca 4
LU - Lussemburgo 4
MU - Mauritius 4
MY - Malesia 4
NP - Nepal 4
PT - Portogallo 4
QA - Qatar 4
AM - Armenia 3
BB - Barbados 3
BH - Bahrain 3
BO - Bolivia 3
CR - Costa Rica 3
HU - Ungheria 3
KH - Cambogia 3
LV - Lettonia 3
NO - Norvegia 3
SN - Senegal 3
SY - Repubblica araba siriana 3
BW - Botswana 2
BY - Bielorussia 2
GE - Georgia 2
GR - Grecia 2
HR - Croazia 2
LK - Sri Lanka 2
Totale 50.043
Salva come PNG Salva come JPEG
Città #
Santa Clara 5.593
Warsaw 3.114
Fairfield 2.627
Ashburn 2.063
Singapore 1.747
Chandler 1.407
Hong Kong 1.266
Dublin 1.265
Woodbridge 1.248
Seattle 1.079
Cambridge 990
Houston 967
Seoul 888
Wilmington 862
Jacksonville 793
Ann Arbor 568
Beijing 551
Hefei 527
San Jose 444
Florence 391
Princeton 351
Buffalo 345
Lawrence 309
Altamura 285
Los Angeles 280
Boston 258
Moscow 212
New York 198
Mumbai 191
Boardman 187
The Dalles 185
Dallas 179
Melbourne 164
Munich 153
Helsinki 142
San Diego 138
Medford 136
Shanghai 130
Kent 126
Ho Chi Minh City 121
Turku 93
Clifton 91
São Paulo 78
Hanoi 73
Norwalk 66
Jakarta 64
Izmir 62
Brussels 61
Falls Church 55
London 55
Chicago 54
Redondo Beach 54
Abidjan 46
Bern 44
Paris 43
Milan 41
West Jordan 41
Barcelona 40
Dong Ket 40
Toronto 40
Tokyo 37
Orem 36
Hillsboro 35
Rio de Janeiro 34
Andover 32
Bremen 32
Phoenix 32
Rome 31
Yubileyny 31
Belo Horizonte 30
Hangzhou 29
Frankfurt am Main 28
Verona 26
Bologna 25
Denver 25
Stockholm 25
Amsterdam 24
Tianjin 24
Vienna 23
Auburn Hills 22
Brooklyn 22
Council Bluffs 22
Johannesburg 22
Montreal 22
Poplar 22
Atlanta 20
Baghdad 20
Curitiba 20
Porto Alegre 20
Arezzo 19
Bengaluru 18
Chennai 18
Guangzhou 18
Manchester 18
Sofia 18
Tashkent 18
Dhaka 17
Campinas 16
Falkenstein 16
Mexico City 16
Totale 34.584
Salva come PNG Salva come JPEG
Nome #
2D-DIGE analysis of ovarian cancer cell responses to cytotoxic gold compounds 356
Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study. 351
MECHANISMS OF CYTOTOXICITY OF SELECTED ORGANOGOLD(III) COMPOUNDS 350
Solution Chemistry and Cytotoxic Properties of Novel Organogold(III) Compounds 333
Proteomic Analysis of Ovarian Cancer Cell Responses to Cytotoxic Gold Compounds 321
Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies. 318
Bioconjugations of proteins with 19F and nitroxide tags for in vitro and in cell characterization 311
Antiproliferative effects of two gold(I)-N-heterocyclic carbene complexes in A2780 human ovarian cancer cells: A comparative proteomic study 308
A first-in-class and a fished out anticancer platinum compound:: Cis -[PtCl2(NH3)2] and cis -[PtI2(NH3)2] compared for their reactivity towards DNA model systems 307
A Fluorescent Silver(I) Carbene Complex with Anticancer Properties: Synthesis, Characterization, and Biological Studies 297
Proteomic analysis of A2780/S ovarian cancer cell response to the cytotoxic organogold(III) compound Aubipy(c.) 295
Proteomic analysis of the cytotoxic effects induced by the organogold(III) complex Aubipyc in cisplatin-resistant A2780 ovarian cancer cells: further evidence for the glycolytic pathway implication 295
Iridium(I) Compounds as Prospective Anticancer Agents: Solution Chemistry, Antiproliferative Profiles and Protein Interactions for a Series of Iridium(I) N-Heterocyclic Carbene Complexes 289
Systems Biology of the Proteomic Analysis of Cytotoxic Gold Compounds in A2780 Ovarian Cancer Cell Line: A Network Analysis 289
New Insights into the Molecular Mechanisms of Selected Anticancer Metal Compounds through Bioinformatic Analysis of Proteomic Data 287
Proteomic and metallomic strategies for understanding the mode of action of anticancer metallodrugs. 274
Evidence that the antiproliferative effects of auranofin in Saccharomyces cerevisiae arise from inhibition of mitochondrial respiration 268
Gold(III) Compounds as a New Family of Antitumor Compounds 254
Molecular Recognition of Metal Complexes by DNA: A Comparative Study of the Interactions of the Parent Complexes [PtCl(TERPY)]Cl and [AuCl(TERPY)]Cl (2) with Double Stranded DNA 248
Mass spectrometry and metallomics: stability and binding site location in the Cyt c-CDDP model system 243
Mass Spectrometry and Metallomics: binding site location in the Cyt c-CDDP model system 238
Unravelling the Chemical Nature of Copper Cuprizone 236
Exploring metal complexes-protein/peptide interactions by high resolution mass spectrometry 236
Exploring the interactions of a “rule-breaker” iodo-platinum(II) complex with cytochrome c by mass spectrometry 236
Auranofin, Et3PAuCl, and Et3PAuI Are Highly Cytotoxic on Colorectal Cancer Cells: A Chemical and Biological Study 235
Reactions of model proteins with aurothiomalate, a clinically established gold(I) drug: The comparison with auranofin 234
Exploring the interactions between phosphane-based platinum(II) dichlorides and cytochrome c by electrospray ionization high resolution mass spectrometry 232
Bottom-up mass spectrometry proteomics strategies for the identification of metallodrug binding sites on proteins: the search for a general protocol to assess adduct stability 231
Selection and characterization of a human ovarian cancer cell line resistant to auranofin 228
A 1H NMR study of cobalt(II) arsanilazocarboxypeptidase A 223
Replacement of the Thiosugar of Auranofin with Iodide Enhances the Anticancer Potency in a Mouse Model of Ovarian Cancer 222
PtI2(DACH), the iodido analogue of oxaliplatin as a candidate for colorectal cancer treatment: chemical and biological features 220
Bottom-up mass spectrometry proteomics strategies for the identification of metallodrug binding sites on proteins: the search for a general protocol to assess adduct stability 219
Exploring metallodrug-protein interactions by mass spectrometry: comparisons between platinum coordination complexes and an organometallic ruthenium compound. 210
(S)-(+)-2-[2-(Biphenyl-2-yl)-1-methylethyl]-4,5-dihydro-1H-imidazolium hydrogen oxalate 205
New gold carbene complexes as candidate anticancer agents 205
Auranofin and its Analogues Show Potent Antimicrobial Activity Covering Multiresistant Pathogens: Structure-Activity Relationships 204
Trace Copper(II) or Zinc(II) Ions Drastically Modify the Aggregation Behavior of Amyloid-beta(1-42): An AFM Study 203
Chimica generale e inorganica 203
The combined activation of K Ca 3.1 and inhibition of K v 11.1/hERG1 currents contribute to overcome Cisplatin resistance in colorectal cancer cells 203
Design, synthesis and characterisation of new chimeric ruthenium(ii)-gold(i) complexes as improved cytotoxic agents 200
A 2-Dimensional Nmr-Study Of Co(Ii)(7) Rabbit Liver Metallothionein 198
Biological properties of two gold(III) complexes: AuCl3(Hpm) and AuCl2(pm) 198
Cytotoxic properties of a new organometallic platinum(II) complex and its gold(I) heterobimetallic derivatives. 197
Chemistry and Biology of Two Novel Gold(I) Carbene Complexes as Prospective Anticancer Agents 196
Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study. 194
Determinants for Tight and Selective Binding of a Medicinal Dicarbene Gold(I) Complex to a Telomeric DNA G-Quadruplex: a Joint ESI MS and XRD Investigation 193
Insights on the mechanism of thioredoxin reductase inhibition by Gold N-heterocyclic carbene compounds using the synthetic linear Selenocysteine containing C-terminal peptide hTrxR(488-499): An ESI-MS investigation. 191
[Au(9-methylcaffein-8-ylidene)2]+/DNA Tel23 System: Solution, Computational, and Biological Studies 191
Crystallographic evidence for decomposition of dimethylformamide in the presence of ruthenium(III) chloride 187
Clioquinol decreases amyloid-beta burden and reduces working memory impairment in a transgenic mouse model of Alzheimer's disease. 187
Water-soluble Ru(II)- and Ru(III)-halide-PTA complexes (PTA = 1,3,5-triaza-7-phosphaadamantane): Chemical and biological properties 186
Antiproliferative properties and biomolecular interactions of three Pd(II) and Pt(II) complexes 186
The NAMI A-human ferritin system: A biophysical characterization 185
Cytotoxicity and DNA binding properties of a chloro glycylhistidinate gold(III) complex (GHAu). 182
Reactions of Auranofin and Its Pseudohalide Derivatives with Serum Albumin Investigated through ESI-Q-TOF MS 182
Chemistry, antiproliferative properties, tumor selectivity, and molecular mechanisms of novel gold(III) compounds for cancer treatment: a systematic study. 179
Metal-Based Compounds as Prospective Antileishmanial Agents: Inhibition of Trypanothione Reductase by Selected Gold Complexes 179
Chlorido and bromido oxaliplatin analogues as potential agents for CRC treatment: Solution behavior, protein binding and cytotoxicity evaluation 178
Structural Investigation of Cisplatin-Protein Interactions: Selective Platination of His 19 in Cuprozinc Superoxide Dismutase 177
Antiangiogenic Properties Of Selected Ruthenium(III) Complexes That Are Nitric Oxide Scavengers 177
Hypericins and Thioredoxin Reductase: Biochemical and Docking Studies disclose the Molecular Basis for Effective Inhibition by Naphthodianthrones 177
Cisplatin and its dibromido analogue: a comparison of chemical and biological profiles 176
Elucidating the reactivity of Pt(II) complexes with (O,S) bidentate ligands towards DNA model systems 175
Diruthenium Diacetate-Catalyzed Aerobic Oxidation of Hydroxylamines and Improved Chemoselectivity by Immobilization to Lysozyme 175
Mass spectrometry and metallomics: A general protocol to assess stability of metallodrug-protein adducts in bottom-up MS experiments 174
The leading established metal-based drugs: a revisitation of their relevant physico-chemical data 173
ESI mass spectrometry and X-ray diffraction studies of adducts between anticancer platinum drugs and hen egg white lysozyme 173
Gold(III) complexes with hydroxyquinoline, aminoquinoline and quinoline ligands: Synthesis, cytotoxicity, DNA and protein binding studies 172
Clioquinol, a drug for Alzheimer's disease specifically interfering with brain metal metabolism: structural characterization of its Zinc(II) and Copper(II) complexes 171
Arsenoplatin-1 Is a Dual Pharmacophore Anticancer Agent 170
Potent in vitro antiproliferative properties for a triplatinum cluster toward triple negative breast cancer cells 170
Decomposition of ascorbic acid in the presence of cadmium ions leads to formation of a polymeric cadmium oxalate species with peculiar structural features. 169
The Many Lives of Auranofin: How an Old Anti-Rheumatic Agent May Become a Promising Antimicrobial Drug 167
The copper(II) coordination abilities of three novel cyclic tetrapeptides with -His-Xaa-His- motif 167
NAMI-A is highly cytotoxic toward leukaemia cell lines: evidence of inhibition of KCa 3.1 channels 167
A case of extensive protein platination: The reaction of lysozyme with a Pt(ii)-terpyridine complex 166
Cisplatin encapsulation within a ferritin nanocage: A high-resolution crystallographic study 165
H-1-Nmr Studies On Partially And Fully Reduced 2(4fe-4s) Ferredoxin From Clostridium-Pasteurianum 164
Gold(III) complexes with 2-substituted pyridines as experimental anticancer agents: Solution behavior, reactions with model proteins, antiproliferative properties 162
The molecular mechanisms of antimetastatic ruthenium compounds explored through DIGE proteomics 162
A multi-technique approach to predicting the molecular structure of cuprizone in the gas phase and in the crystalline state 162
The mode of action of anticancer gold-based drugs: a structural perspective 162
Structural Characterization of a Gold/Serum Albumin Complex 162
ESI-MS studies of the reactions of novel platinum(II) complexes containing O,O'-chelated acetylacetonate and sulfur ligands with selected model proteins 161
Reaction with proteins of a five-coordinate platinum(II) compound 160
Structural and solution chemistry, antiproliferative effects, and serum albumin binding of three pseudohalide derivatives of auranofin 160
Modeling of copper(II) sites in proteins based on histidyl and glycyl residues 160
A theoretical analysis of the H Nuclear Magnetic Relaxation Dispersion profiles of diferric transferrin 160
Cytotoxicity, DNA damage, and cell cycle perturbations induced by two representative gold(III) complexes in human leukemic cells with different cisplatin sensitivity 160
Chemistry and biology of three representative gold(III) compounds as prospective anticancer agents 160
Synthesis, characterization and DNA interactions of [Pt3(TPymT)Cl3], the trinuclear platinum(II) complex of the TPymT ligand 160
Cytotoxic activity and protein binding through an unusual oxidative mechanism by an iridium(I)–NHC complex 159
Au2phen and Auoxo6, Two Dinuclear Oxo-Bridged Gold({III}) Compounds, Induce Apoptotic Signaling in Human Ovarian A2780 Cancer Cells 159
A BINOL-based chiral polyammonium receptor for highly enantioselective recognition and fluorescence sensing of (S,S)-tartaric acid in aqueous solution 159
Oxaliplatin vs. cisplatin: Competition experiments on their binding to lysozyme 159
Organogold(III) compounds as experimental anticancer agents: chemical and biological profiles 159
Interaction of anticancer Ru(III) complexes with single stranded and duplex DNA model systems 159
The copper(II) binding properties of the cyclic peptide c(HGHK) 158
Exploiting soft and hard x-ray absorption spectroscopy to characterize metallodrug/protein interactions: the binding of [trans-rucl4(im)(dimethylsulfoxide)][imH] (im = imidazole) to bovine serum albumin 158
Totale 20.792
Salva come PNG Salva come JPEG
Categoria #
all - tutte 135.248
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 135.248
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.809 0 0 0 0 0 0 170 303 332 515 199 290
2021/20222.264 78 166 141 91 131 122 74 158 149 118 419 617
2022/20235.754 597 988 288 481 458 1.049 738 304 548 50 157 96
2023/20242.170 91 210 366 107 123 320 101 440 41 102 186 83
2024/202514.908 539 1.554 927 2.149 4.446 2.326 254 644 648 316 512 593
2025/20269.859 1.743 2.338 1.382 1.175 1.787 648 786 0 0 0 0 0
Totale 50.467